卵巢癌不同初始管理策略的总费用与自付费用
基于MarketScan数据库2006—2015年12,761例卵巢癌患者的观察性队列研究,计算初始治疗后8个月内总费用与自付费用并统一为2017年美元。新辅助化疗者调整后平均总费用高于初次减瘤术者,含贝伐珠单抗方案总费用高于不含者,高免赔额保险计划参保者自付负担较重。
要点
- 新辅助化疗者调整后平均总费用$113,660,高于初次减瘤术者的$107,153(P<.001)。
- 含贝伐珠单抗方案总费用$171,468,高于不含者的$104,482(P<.001)。
- 高免赔额保险计划参保者自付费用中位数$4196,25%支付≥$6680。
核心结论
- 不同治疗策略的费用存在差异,患者承担显著的自付负担,高免赔额保险计划参保者尤为突出。
研究设计与样本
- 观察性队列研究,从MarketScan数据库识别2006—2015年接受卵巢癌治疗的女性12,761例。
- 费用按初始治疗后8个月内所有理赔计算,并统一折算为2017年美元。
- 采用广义线性模型评估不同策略的费用。
主要发现
- 新辅助化疗者与初次减瘤术者的调整后平均总费用分别为$113,660与$107,153(P<.001),平均自付费用分别为$2519与$2977(P<.001)。
- 静脉标准化疗、静脉剂量密集化疗、腹腔/静脉化疗的总费用分别为$105,047、$115,099、$121,761(P<.001),自付费用分别为$2838、$3405、$2888(P<.001)。
- 含贝伐珠单抗方案与不含贝伐珠单抗方案的总费用分别为$171,468与$104,482(P<.001),自付费用分别为$3127与$2898(P<.001)。
- 未接受贝伐珠单抗者中,25%支付≥$3875,10%支付≥$6265;接受贝伐珠单抗者中,25%支付≥$4480,10%支付≥$6635。
- 高免赔额保险计划参保者自付费用中位数为$4196,25%支付≥$6680,10%支付≥$9751。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Communicating healthcare costs to patients is an important component of delivering high-quality value-based care, yet cost data are lacking. This is especially relevant for ovarian cancer, where no clinical consensus on optimal first-line treatment exists. OBJECTIVE: The objective of this study was to generate cost estimates of different primary management strategies in ovarian cancer. STUDY DESIGN: All women who underwent treatment for ovarian cancer from 2006-2015 were identified from the MarketScan database (n=12,761) in this observational cohort study. Total and out-of-pocket costs were calculated with the use of all claims within 8 months from initial treatment and normalized to 2017 US dollars. The generalized linear model method was used to assess cost by strategy. RESULTS: Among patients who underwent neoadjuvant chemotherapy and those who underwent primary debulking, mean adjusted total costs were $113,660 and $107,153 (P<.001) and mean out-of-pocket costs were $2519 and $2977 (P<.001), respectively. Total costs for patients who had intravenous standard, intravenous dose-dense, and intraperitoneal/intravenous chemotherapy were $105,047, $115,099, and $121,761 (P<.001); and out-of-pocket costs were $2838, $3405, and $2888 (P<.001), respectively. Total costs for regimens that included bevacizumab were higher than those without it ($171,468 vs $104,482; P<.001); out-of-pocket costs were $3127 vs $2898 (P<.001). Among patients who did not receive bevacizumab, 25% paid ≥$3875, and 10% paid ≥$6265. For patients who received bevacizumab, 25% paid ≥$4480, and 10% paid ≥$6635. Among patients enrolled in high-deductible health plans, median out-of-pocket costs were $4196, with 25% paying ≥$6680 and 10% paying ≥$9751. CONCLUSION: Costs vary across different treatment strategies, and patients bear a significant out-of-pocket burden, especially those enrolled in high-deductible health plans.
引用
- Suidan RS, He W, Sun CC, et al. Total and out-of-pocket costs of different primary management strategies in ovarian cancer. Am J Obstet Gynecol. 2019. PMID: 30965052. doi:10.1016/j.ajog.2019.04.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。